Life Sciences Blog

23andMe will no longer provide genetic test data on health risks

Posted on December 6th, by Michael Shapiro-Barr

The genetic testing firm, 23andMe, has said that they will no longer provide consumers with health information while its test undergoes regulatory review.  This decision comes after the FDA sent a warning letter to 23andMe, classifying the genetic test as a medical device, requiring approval.  23andMe will continue to provide ancestry information and raw data, leaving out interpretations of the health implications.

Read More



Leave a Reply

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Media Quotes

  • Mercedes Meyer, a patent lawyer with the firm Drinker Biddle in Washington, D.C., said the Supreme Court’s failure to provide “bright-line guidance”—a ruling that would settle once-and-for all whether patent settlements are legal or not—means there’s “really no difference now than what was going on.” Mercedes Meyer
    CNBC: High Court Allows FTC to Challenge 'Pay-to-Delay' Generics

From the Blog

The Debate Over Mobile Health Software Regulation

On November 19th, the House Energy and Commerce Subcommittee on Health held a hearing to examine the federal regulation of mobile medical applications (mobile...

23 Skidoo – Genomes, Gamesmanship and the First Amendment

On November 22, 2013, the Inquisition collided with the Internet.  On that date, the Food and Drug Administration issued a Warning Letter threatening 23andMe,...

FDA’s Warning Letter to 23andMe: Ethical and Legal Issues

The FDA’s warning letter to 23andMe, the maker of mail-order genetic tests, highlights the challenging legal and ethical issues posed by such products.  While...